Cargando…

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer

Detalles Bibliográficos
Autores principales:	Weeraman, S, Hunsley, C, Wall, M, Kirby, R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875608/ http://dx.doi.org/10.1186/bcr2543

Ejemplares similares

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment
por: Gobbi, Silvia, et al.
Publicado: (2023)

Use of aromatase inhibitor in a girl with peripheral precocious puberty
por: Lee, CY, et al.
Publicado: (2013)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

Dysregulated metabolism and the regulation of aromatase in breast adipose stromal cells in obesity and cancer
por: Samarajeewa, Nirukshi U, et al.
Publicado: (2012)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

The “tweaking principle” for task switching
por: Ardid, Salva, et al.
Publicado: (2014)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity
por: Stone, A, et al.
Publicado: (2008)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Role of p27 in tamoxifen response in breast cancer cell lines
por: Nilsson, S, et al.
Publicado: (2009)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Harrigan, Maura, et al.
Publicado: (2021)

Dynamical switching between different hippocampal rhythms
por: Lavrova, Anastasia I, et al.
Publicado: (2011)

AB081. Effects of combination therapy of Tamoxifen, L-carnitine and daily PDE5 inhibitors in the Peyronie’s disease
por: Kang, Jae Il, et al.
Publicado: (2016)

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen
por: Lehn, S, et al.
Publicado: (2009)

PB.43. A clinical audit of breast cancer staging
por: Sulistijo, A, et al.
Publicado: (2014)

Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models
por: Polson, E, et al.
Publicado: (2008)

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study
por: Ng, Huah Shin, et al.
Publicado: (2018)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Management of needle stick injuries from incapacitated patients
por: Burrows, L, et al.
Publicado: (2010)

Needle-stick injuries in Isfahan, Iran: quality improvement
por: Mobasherizadeh, S, et al.
Publicado: (2011)

An improved translational switch for long term maintenance of synaptic plasticity
por: Agarwal, Animesh, et al.
Publicado: (2010)

Switching to an alternative biological agent in juvenile idiopathic arthritis (I)
por: Remesal, A, et al.
Publicado: (2011)

Switching to an alternative biological agent in juvenile idiopathic arthritis (II)
por: Murias, S, et al.
Publicado: (2011)

Competing MYB networks as switches in primary and secondary metabolism in spruce
por: Bomal, Claude, et al.
Publicado: (2011)

A model for dynamical switching in tristable perception for visual plaids
por: Huguet, Gemma, et al.
Publicado: (2012)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

Audit of a radiographer/nurse-led family history breast cancer clinic
por: Willson, SA, et al.
Publicado: (2008)

PB.44: Audit of interval cancers from family history breast screening
por: Dunn, R, et al.
Publicado: (2013)

An audit of pain in ultrasound-guided breast core biopsy
por: Whelehan, P, et al.
Publicado: (2010)

An audit of preoperative magnetic resonance imaging staging of the breast
por: Bagnall, M, et al.
Publicado: (2006)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k7mf0e34o4t0vlqo3ccsrhvibj